The company said premium and service revenues for Q3 2024 were $36.9 billion, up 6% from a year earlier. Diluted EPS was $1.36 (vs. $0.87 for Q3 2023), and adjusted diluted EPS was $1.62 (vs. $2.00 for Q3 2023).

1. 01

   The company said premium and service revenues for Q3 2024 were $36.9 billion, up 6% from a year earlier. Diluted EPS was $1.36 (vs. $0.87 for Q3 2023), and adjusted diluted EPS was $1.62 (vs. $2.00 for Q3 2023).

2. 02

   Centene said the HBR for Q3 2024 was 89.2%, higher than the 87.0% for the same period in 2023. The company cited higher Medicaid acuity from the redetermination process and Medicare Star rating impacts as the factors.

3. 03

   Centene said operating activities generated $741 million of cash in the 9 months ended September 30, 2024 (vs. $7.8 billion in the same period a year earlier). Financing activities used $2.4 billion, of which stock repurchases were $2.2 billion.

4. 04

   Centene said it repurchased 16.3 million shares for $1.2 billion under its stock repurchase program in Q3 2024. It said about $3.2 billion remained available under the program as of September 30, 2024.

Key figures

Quarter ended September 30, 2024

Operating income

$665M

Net income

$713M

EPS

$1.36

Gross profit

$4.0B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.